Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report details a specific share repurchase transaction executed on September 6, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,550,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,442.0 pence per share; lowest price paid was 1,418.0 pence per share.
- Treasury Holdings (Settled): 504,608,927 shares, representing 9.22% of total issued share capital.
- Treasury Holdings (Including Unsettled): 509,482,427 shares, representing 10.26% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,967,694,398 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 1,550,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.26% when including unsettled purchases. The filing does not provide comparative financial data to assess material changes in operational performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (504,608,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,967,694,398 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,418.0 to 1,442.0 pence) against market prices on September 6, 2012.
- Note that this filing does not contain operational financial results; refer to Form 20-F or interim reports for revenue and profit data.